Literature DB >> 19404178

Outcome of conservative surgery for giant cell tumor of the sacrum.

Wei Guo1, Tao Ji, Xiaodong Tang, Yi Yang.   

Abstract

STUDY
DESIGN: Retrospective analysis.
OBJECTIVE: To estimate the clinical outcome of conservative surgery (intralesional curettage or partial excision) aided by effective intraoperative hemorrhage control in patients with giant cell tumors of the sacrum. SUMMARY OF BACKGROUND DATA: Giant cell tumors of the sacrum present a challenging therapeutic problem. Wide resection is associated with higher morbidity and spinal instability. Whether conservative surgery aided by effective intraoperative hemorrhage control can achieve low recurrence rates remains uncertain.
METHODS: The clinical records of 24 patients with an average age of 35 years who had undergone conservative surgery for sacral giant cell tumor between 1996 and 2005 were evaluated retrospectively. The disease onset, tumor size, operation records, complications, follow-up status, and functional outcome were analyzed.
RESULTS: The mean duration of follow-up was 58 months (median, 50 months; range: 25-132 months). All the patients had a conservative procedure aided by intraoperative occlusion of the abdominal aorta. The mean estimated blood loss was 3217 mL. The mean length of the operation was 190 minutes. Seven (29.2%) patients developed recurrences. The mean time from the index surgical procedure to the first recurrence was 13 months (range: 8-31 months). The 5-year local recurrence-free survival rate was 69.6%. Seventeen (70.8%) patients retained normal urinary function and 16 (66.7%) patients preserved normal bowel function. No patients had urinary or bowel dysfunction when both S3 nerves were preserved. Ten (41.7%) patients had complications perioperatively or during the follow-up. Seven (29.2%) patients had wound complications.
CONCLUSION: Considering the acceptable local recurrence rate, conservative surgery aided by effective control of intraoperative hemorrhage should be considered as an alternative procedure for patients with giant cell tumors of the sacrum. The advantages include lower morbidity, reduced neurologic deficits, speed and ease of the surgical procedure, reduced blood loss, preservation of spinal and pelvic continuity, and a low recurrence rate.

Entities:  

Mesh:

Year:  2009        PMID: 19404178     DOI: 10.1097/BRS.0b013e31819d4127

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  30 in total

1.  Bilateral Hydronephrosis Secondary to Giant Cell Tumor of the Sacrum.

Authors:  Omer Farooq Rehman; Amer K Hussain; Mohammad Ummair; Musab Umair; Muhammad Waqar
Journal:  Cureus       Date:  2020-12-15

Review 2.  Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.

Authors:  Christopher Martin; Edward F McCarthy
Journal:  Iowa Orthop J       Date:  2010

3.  Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor.

Authors:  Pietro Ruggieri; Andreas F Mavrogenis; Giuseppe Ussia; Andrea Angelini; Panayiotis J Papagelopoulos; Mario Mercuri
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

4.  Conservative surgery in the treatment of giant cell tumor of the sacrum: 35 years' experience.

Authors:  Stepan V Domovitov; Chandhanarat Chandhanayingyong; Patrick J Boland; David G McKeown; John H Healey
Journal:  J Neurosurg Spine       Date:  2015-10-30

5.  Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision.

Authors:  L van der Heijden; M A J van de Sande; I C M van der Geest; H W B Schreuder; B J van Royen; P C Jutte; J A M Bramer; F C Öner; A P van Noort-Suijdendorp; H M Kroon; P D S Dijkstra
Journal:  Eur Spine J       Date:  2014-03-11       Impact factor: 3.134

6.  Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis.

Authors:  K Zhang; M Zhou; H Chen; G Wu; K Chen; H Yang
Journal:  Clin Transl Oncol       Date:  2015-03-05       Impact factor: 3.405

7.  Giant Cell Tumor of the Sacrum: Series of 19 Patients and Review of the Literature.

Authors:  Khodamorad Jamshidi; Abolfazl Bagherifard; Alireza Mirzaei; Mehrdad Bahrabadi
Journal:  Arch Bone Jt Surg       Date:  2017-11

8.  Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage.

Authors:  Kun-Hui Chen; Po-Kuei Wu; Cheng-Fong Chen; Wei-Ming Chen
Journal:  Eur Spine J       Date:  2015-05-05       Impact factor: 3.134

9.  Can Aortic Balloon Occlusion Reduce Blood Loss During Resection of Sacral Tumors That Extend Into the Lower Lumber Spine?

Authors:  Yidan Zhang; Wei Guo; Xiaodong Tang; Rongli Yang; Taiqiang Yan; Sen Dong; Shidong Wang; Nikolas Zaphiros
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

10.  What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?

Authors:  Tao Ji; Wei Guo; Rongli Yang; Xiaodong Tang; Yifei Wang; Lin Huang
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.